SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3556-3559. Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-04-014514. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-014514v1 108/10/3556    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Burmeister, T. Articles by Schwartz, S. Search for Related Content PubMed PubMed Citation Articles by Burmeister, T. Articles by Schwartz, S. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 4, 2006 Accepted July 10, 2006 NUP214-ABL1 in adult T-ALL: the GMALL study group experience Thomas Burmeister*, Nicola Gokbuget, Richard Reinhardt, Harald Rieder, Dieter Hoelzer, and Stefan Schwartz Charite Universitatsmedizin Berlin Johann Wolfgang Goethe Universitat Frankfurt Max Planck Institut fur Molekulare Genetik Heinrich-Heine-Universitat Dusseldorf * Corresponding author; email: thomas.burmeister{at}charite.de. The NUP214-ABL1 fusion gene in T-ALL has recently been identified as a possible target for imatinib and related tyrosine kinase inhibitors but exact data regarding prognostic impact and frequency of the several putative NUP214-ABL1 mRNA transcripts are still missing. We have investigated 279 adult T-ALL patients treated within the framework of the GMALL 5/93 and 6/99 therapy trials for NUP214-ABL1 by using a novel multiplex real-time quantitative PCR. Eleven (3.9%) patients were NUP214-ABL1-positive and 5 different transcripts were observed; 8 patients had a thymic, 1 an early T- and 2 a mature T-immunophenotype. NUP214-ABL1-positive and -negative patients did not differ significantly in their major clinical features, and in contrast to previous reports suggesting an adverse clinical course of NUP214-ABL1-positive patients, no significant difference in overall survival was observed. Based on the results, we have established and tested a novel PCR method for simplified detection of the NUP214-ABL1 fusion gene. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Fischer, N. Gokbuget, S. Schwartz, T. Burmeister, H. Rieder, M. Bruggemann, D. Hoelzer, and E. Thiel CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy Haematologica, February 1, 2009; 94(2): 224 - 229. [Abstract] [Full Text] [PDF] F. Baleydier, A.-V. Decouvelaere, J. Bergeron, P. Gaulard, D. Canioni, Y. Bertrand, S. Lepretre, B. Petit, H. Dombret, K. Beldjord, et al. T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome Clin. Cancer Res., February 1, 2008; 14(3): 692 - 700. [Abstract] [Full Text] [PDF] S. Chiaretti, S. Tavolaro, E. M. Ghia, C. Ariola, C. Matteucci, L. Elia, R. Maggio, M. Messina, M. R. Ricciardi, A. Vitale, et al. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis Haematologica, May 1, 2007; 92(5): 619 - 626. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020